Effect of Low-Dose Carperitide in Patients With Acute Decompensated Heart Failure The Randomized Trial (Low-dose AdminiStration of CARperitide for Acute Heart Failure:LASCAR-AHF study)

Effect of Low-Dose Carperitide in Patients With Acute Decompensated Heart Failure The Randomized Trial (Low-dose AdminiStration of CARperitide for Acute Heart Failure:LASCAR-AHF study) - Low-Dose Carperitide on Acute Decompensated Heart Failure

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013819

Enrollment

260

Registered

2014-05-26

Start date

2014-09-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Decompensated Heart Failure

Interventions

Control (without HANP) 1. Frosemide 40mg/day 24hours after randomization 2. Twice frosemide dose of 7 days before admission. 3. Dietary restriction (Sodium: 6000mg/day, Water: 1500mL/day) 4. Treat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosis of Acute HF At least 1 symptom (dyspnea, orthopnea, or edema) At least 1 sign (rales, edema, ascites, chest radiographic signs of HF) Enrolled within 6 hours of hospital admission Age above 20, below 85 years Systolic BP 100 mmHg and above Willingness to provide written informed consent

Exclusion criteria

Exclusion criteria: No indication of intravenous vasodilators or diuretics for initial treatments Carperitide administration before randomization Receiving dialysis eGFR less than 15 mL/min/1.73m2 Acute coronary syndrome Possible for pregnancy Enrolled other clinical trials

Design outcomes

Primary

Measure	Time frame
Composite of all-cause death and HF hospitalization events of HF hospitalizations must have clinical manifestations of worsening HF (new or worsening dyspnea, orthopnea, paroxysmal nocturnal dyspnea, edema, pulmonary basilar rales/crackles, jugular venous distension, renal hypoperfusion with no other apparent cause, or radiological evidence of worsening HF) and additional/increased therapy, specifically for the treatment of worsening HF with at least one of the following: 1. Intravenous treatment with a diuretic, inotropic, vasodilator, or other recognized intravenous HF treatment 2. Mechanical or surgical intervention (mechanical circulatory support) or the use of ultrafiltration, hemofiltration, or dialysis specifically directed at treatment of HF	—

Measure

Time frame

Composite of all-cause death and HF hospitalization events of HF hospitalizations must have clinical manifestations of worsening HF (new or worsening dyspnea, orthopnea, paroxysmal nocturnal dyspnea, edema, pulmonary basilar rales/crackles, jugular venous distension, renal hypoperfusion with no other apparent cause, or radiological evidence of worsening HF) and additional/increased therapy, specifically for the treatment of worsening HF with at least one of the following: 1. Intravenous treatment with a diuretic, inotropic, vasodilator, or other recognized intravenous HF treatment 2. Mechanical or surgical intervention (mechanical circulatory support) or the use of ultrafiltration, hemofiltration, or dialysis specifically directed at treatment of HF

—

Secondary

Measure	Time frame
Decongestion Cumulative urinary volume at 72 h Urinary sodium excretion at 72 h Change in body weight from randomization to 72 h Symptom relief Change in degree of dyspnea assessed by area under the curve of visual analogue scale over 72 h Renal function Change in eGFR from randomization to 72 h Serum cystatin-C level from randomization to 72 h Biomarkers Change in plasma brain natriuretic peptide, renin, aldosterone, dopamine, adrenaline and noradrenaline levels, and serum sodium, potassium, chloride and neutrophil gelatinase-associated lipocalin levels from randomization to 72 h	—

Measure

Time frame

Decongestion Cumulative urinary volume at 72 h Urinary sodium excretion at 72 h Change in body weight from randomization to 72 h Symptom relief Change in degree of dyspnea assessed by area under the curve of visual analogue scale over 72 h Renal function Change in eGFR from randomization to 72 h Serum cystatin-C level from randomization to 72 h Biomarkers Change in plasma brain natriuretic peptide, renin, aldosterone, dopamine, adrenaline and noradrenaline levels, and serum sodium, potassium, chloride and neutrophil gelatinase-associated lipocalin levels from randomization to 72 h

—

Countries

Japan

Contacts

Public ContactToshiyuki Nagai

Hokkaido University Cardiovascular Medicine

nagai@med.hokudai.ac.jp011-706-6973

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026